PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.

ABSTRACT:

Background and objectives

The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that intensive BP lowering reduced the risk of cardiovascular disease, but increased eGFR decline. Serum parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23) concentrations are elevated in CKD and are associated with cardiovascular disease. We evaluated whether intact PTH or intact FGF23 concentrations modify the effects of intensive BP control on cardiovascular events, heart failure, and all-cause mortality in SPRINT participants with CKD.

Design, setting, participants, & measurements

We measured PTH and FGF23 in 2486 SPRINT participants with eGFR<60 ml/min per 1.73 m² at baseline. Cox models were used to evaluate whether serum PTH and FGF23 concentrations

SUBMITTER: Ginsberg C 

PROVIDER: S-EPMC6302330 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature